Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 941

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 9
Chunk 941
---
 accounting function to segregate the duties over financial transaction processing and reporting. Because of this material weakness, management concluded that the Company’s internal control over financial reporting was not effective as of December 31, 2024.

Continuing Remediation Efforts

To remediate its internal control weakness, management intends to implement the following measures, as the Company’s resources and financial means allow:

 ·Add additional accounting personnel or outside consultants, such as a new controller, to properly segregate duties and to effect timely, accurate preparation of the financial statements; and    ·Complete the development of and maintain adequate written accounting policies and procedures.

As we are not an “accelerated filer” under SEC rules, we are not required to provide an auditor’s attestation of management’s assessment of internal control over financial reporting as of December 31, 2024. 

Changes in Internal Control of Financial Reporting

During the three months ended December 31, 2024, except as described above under “Continuing Remediation Efforts,” there were no changes that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information.

During the three months ended December 31, 2024, none of our directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not applicable.

 53Table of Contents

PART III

Item 10. Directors, Executive Officers and Corporate Governance. 

The following table sets forth the names and ages of all of our executive officers and directors. Our officers are appointed by, and serve at the pleasure of, the board of directors.

Name Age PositionAlexander Tokman 63 Acting Chief Executive Officer and ChairmanMichael Thornton 56 Chief Technology OfficerRichard Jacroux 57 Chief Financial OfficerLouis J. Basenese 47 DirectorAnthony DiGiandomenico 58 DirectorMichael Harsh 70 Director

Biographical information with respect to our executive officers and directors is provided below. There are no family relationships between any of our executive officers or directors.

Alexander Tokman joined ENDRA’s Board of Directors in 2008 and was appointed as the Company’s acting Chief Executive Officer and Chairman of the Board of Directors on August 13